NCT05095181

Brief Summary

The purpose of this study is to identify genetic determinants of susceptibility to liver cirrhosis . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of liver cirrhosis .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 29, 2021

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 21, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 27, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

1.8 years

First QC Date

October 21, 2021

Last Update Submit

March 13, 2023

Conditions

Liver Cirrhosis

Keywords

SNP

Outcome Measures

Primary Outcomes (1)

  • genotyping for the SNP associated with liver cirrhosis

    Genotype frequency of SNP in the study genes of participants and control participants.

    1 year

Study Arms (2)

Experimental group:

patients with liver cirrhosis

Genetic: SNP analysis of the DNA

Control group

patients without liver cirrhosis

Genetic: SNP analysis of the DNA

Interventions

SNP analysis of the DNAGENETIC

SNP analysis of the DNA obtained from peripheral blood sample

Control groupExperimental group:

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

KAZAKH POPULATION

You may qualify if:

  • hepatitis B

You may not qualify if:

  • the casual aget of liver disease is not viral infection, such as alcohol abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Scientific Center of Surgery named after A.N. Syzganova

Almaty, Kazakhstan

Location

Related Publications (1)

  • Ilyassova BS, Abzhaparova B, Smailova DS, Bolatov A, Baymakhanov B, Beloussov V, Solomadin M, Shamsivaliyeva K, Alpysbayava G, Issakova G, Granica J, Mukushkina D, Sagatov IY, Kaniyev S. Prevalence and genotypes distribution of virus hepatitis B and hepatitis delta virus in chronic liver diseases in Kazakhstan. BMC Infect Dis. 2023 Aug 14;23(1):533. doi: 10.1186/s12879-023-08524-1.

    PMID: 37580657DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Bibigul Saparbekovna, PhD

    JSC "National Scientific Center of Surgery named after A.N. Syzganova "

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Laboratory of Experimental Medicine

Study Record Dates

First Submitted

October 21, 2021

First Posted

October 27, 2021

Study Start

March 29, 2021

Primary Completion

January 20, 2023

Study Completion

January 20, 2023

Last Updated

March 14, 2023

Record last verified: 2023-03

Locations

KA(1)